

CP-547632

Chemical Properties


CAS No. : 252003-65-9

Formula: C₂₀H₂₄BrF₂N₅O₃S

Molecular Weight: 532.4

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC ₅₀ s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFR β and related tyrosine kinases (TKs). PDGFR β and related tyrosine kinases (TKs) CP-547632 has antitumour activity.
Targets(IC ₅₀)	FGFR,BTK,PDGFR,VEGFR
In vitro	CP-547632 (1-1000 nM ; 1 h) suppresses VEGF-induced VEGFR-2 phosphorylation in a concentration-dependent manner (IC ₅₀ : 6 nM). [1]
In vivo	CP-547632 (oral ; 50 mg/kg) yields plasma concentrations above 500 ng/ml for 12 hours. CP-547632 (p.o. ; 6.25-100 mg/kg/day ; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.[1]

Solubility Information

Solubility	DMSO: 90 mg/mL (169.05 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.51 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8783 mL	9.3914 mL	18.7829 mL
5 mM	0.3757 mL	1.8783 mL	3.7566 mL
10 mM	0.1878 mL	0.9391 mL	1.8783 mL
50 mM	0.0376 mL	0.1878 mL	0.3757 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Beebe JS, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. *Cancer Res.* 2003 Nov 1 ; 63(21):7301-9.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481